Searched for
RANBAXY EARNINGS
Sun's strong gravity helps India Inc's pullSun Pharma has expanded its horizons by acquiring Organon, a notable New Jersey pharmaceutical firm. This strategic acquisition fortifies S...- ET Exclusive | Sun Pharma set to acquire Organon for $12.5 bn, its biggest till dateUS company’s board meeting is happening this weekend to finalise decision; an announcement is imminent later tonight or by Monday. Mumbai H...
- Ranbaxy to launch generic Diovan in USRanbaxy’s CEO had said in a conference call that the company is confident that retains the exclusivity opportunities in US and would moneti...
- Quarterly numbers not to impact Ranbaxy: Harendra Kumar"Ranbaxy's performance is not a surprise. Most of us were fundamentally negative on the outcome of quarterly numbers."
- Wait for the right time to buy Ranbaxy: Neeraj Deewan"One cannot have some reaction in the stock price in the couple of days or maybe week to follow but then it will get price adjusted."
- Bullish on pharma sector: Sonam Udasi, IDBI CapitalIn a chat with ET Now, Sonam Udasi, Head of Research, IDBI Capital, shares his views on Ranbaxy.
- Ranbaxy, the next big story in pharma space: Prakash Diwan"Finally, the good times are here for Ranbaxy. It has a potential to be into the 1000 category in about 18 months' time."
- Ranbaxy suffers Rs 524-crore net loss in June quarterNet sales was down to Rs 2,633.20 crore for the quarter ended June, as against Rs 3,204.59 crore in the corresponding period last year.
- Ranbaxy: Improving US, local businesses to keep stock upRanbaxy’s September quarter performance, which was sans the exclusivity sales of generic Lipitor, was boosted by two authorised generic lau...
- Ranbaxy Q3 top-line seen up 33% at Rs 2698 croreRanbaxy is expected to report a 33 per cent jump in its net sales for the quarter ended September 30 to Rs 2698 crore.
- Ranbaxy's party may be spoiled by too many playersWhile Ranbaxy did secure the final approval of the USFDA to launch the generic version of Lipitor on time, there are too many players to sp...
- Ranbaxy launches low-cost version of medicine 'Lipitor'The US FDA allowed Ranbaxy to make and sell atorvastatin tablets, the chemical name of Lipitor, ending months of uncertainty.
- Ranbaxy a good buy opportunity: Deven ChokseyRanbaxy would have a tendency to jump up. So maybe 10% fall from here, it would be a good buy opportunity to get into Ranbaxy.
- Ranbaxy to supply raw materials for anti-ulcer drugRanbaxy Laboratories, India's largest company by sales, is expected to start supplying raw materials for anti-ulcer drug esomeprazole magne...
- Reliance Money upgrades Ranbaxy to ‘BUY’; target price Rs 189Given the attractive valuations at current levels, Reliance Money has upgraded its rating on Ranbaxy Laboratories from ‘hold’ to ‘buy’ with...
- Ranbaxy down another 4% weighed by USFDA actionShares of Ranbaxy Laboratories continued to witness fresh selling pressure on Friday. The stock was trading at Rs 164, losing another 4% in...
- Ranbaxy misses deadline for migraine drug launchIndia's largest drugmaker, Ranbaxy Laboratories, has missed its December 2008 deadline to launch an anti-migraine drug as the US regulator ...
- Post USFDA ban, Ranbaxy readies plan B for drugsRanbaxy may shift production of the $1.5-billion drug Valacyclovir to its other FDA- approved facilities. The Top 10 food myths revealed | ...
- UBS downgrades its ratings on RanbaxyUBS has downgraded its ratings on Ranbaxy from "neutral" to "sell", citing the ongoing investigation by the US Food and Drug Administration...
- Ranbaxy to tap South African marketPharma major Ranbaxy Laboratories on Tuesday said the acquisition of Be-Tabs Pharmaceuticals (Pty) Ltd (Be-Tabs) has been further strengthe...
Load More
